PRTA vs. ELVN, ABCL, VRNA, COLL, MIRM, IRWD, INVA, SAVA, BLTE, and MNKD
Should you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Verona Pharma (VRNA), Collegium Pharmaceutical (COLL), Mirum Pharmaceuticals (MIRM), Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), Cassava Sciences (SAVA), Belite Bio (BLTE), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
Enliven Therapeutics (NASDAQ:ELVN) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Prothena received 596 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 70.67% of users gave Prothena an outperform vote.
95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 45.8% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 28.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Enliven Therapeutics has a net margin of 0.00% compared to Enliven Therapeutics' net margin of -193.17%. Prothena's return on equity of -28.83% beat Enliven Therapeutics' return on equity.
Enliven Therapeutics has higher earnings, but lower revenue than Prothena. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Enliven Therapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 47.57%. Prothena has a consensus price target of $67.00, suggesting a potential upside of 197.51%. Given Enliven Therapeutics' higher possible upside, analysts plainly believe Prothena is more favorable than Enliven Therapeutics.
Enliven Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.
In the previous week, Enliven Therapeutics had 4 more articles in the media than Prothena. MarketBeat recorded 13 mentions for Enliven Therapeutics and 9 mentions for Prothena. Prothena's average media sentiment score of 0.75 beat Enliven Therapeutics' score of 0.37 indicating that Enliven Therapeutics is being referred to more favorably in the media.
Summary
Enliven Therapeutics beats Prothena on 10 of the 17 factors compared between the two stocks.
Get Prothena News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prothena Competitors List
Related Companies and Tools
